Effect of Tinzaparin on inflammatory biomarkers during the acute phase of deep vein thrombosis

CHU Amiens-Picardie0 个研究点目标入组 12 人开始时间: 2020年11月30日最近更新: 2024年1月8日

试验速览

暂无简介。

•- Adult patients with a first episode of symptomatic, proximal DVT of the lower limbs, confirmed by Duplex Ultrasound (DUS)
•- Indication for treatment with Tinzaparin
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 8
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 4

•- Recent DVT (less than 2 months) other than the index event with or without PE
•- Severe ilio-femoral DVT requiring recanalization
•- Duration of treatment of more than 24 h since diagnosis
•- Planned surgery in the following 3 weeks, impossible to postpone
•- Active haemorrhage or high risk of haemorrhage
•- Symptoms of Post Thrombotic Syndrome
•- Active neoplasm
•- APL syndrome
•- Renal insufficiency (Creatinine clearance (Cockcroft-Gault) <20 mL/min)
•-Hepatic disease / or Hepatic Insufficiency / or serious liver disease
•- Any anti-inflammatory drugs or anti-platelet therapy
•- Any other concomitant anticoagulant treatment such as VKA, heparin, fondaparinux
•- Contraindications to LMWH according to their SmPC

发起方

CHU Amiens-Picardie